ArticleMethods in molecular biology (Clifton, N.J.)2026
Methods for Investigating Siglec-Ganglioside Interactions.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Siglecs are a family of cell surface receptors generally found on immune cells, which are important in many cellular processes such as cell-adhesion, cell-signaling, and internalization of extracellular particles. While all these smaller functions play a part in larger and different physiological roles, one aspect they share is that they are initiated by the binding of a Siglec to its ligand. Siglec ligands are cell-surface carbohydrates appended to proteins and lipids that terminate with the monosaccharide sialic acid. The functions of a Siglec are directly linked to the binding of its ligands. There has been a great effort by many research teams over the past three decades to describe Siglec ligands to better understand their roles in health and disease. The systematic description of Siglec ligands has revealed that Siglecs are important in a range of physiological processes, including but not limited to allergies, antibody production, cancer progression, and reproduction. However, despite these efforts, the description of Siglec ligands remains incomplete. Historically Siglec-glycoprotein interactions have been better described compared to Siglec-glycolipid interactions; this is likely due to the combination of the relative difficulty in studying Siglec-glycolipid interactions and the dearth of tools available to study these interactions. Gangliosides are the major class of sialylated glycolipids in mammals. In this chapter, three protocols used to investigate Siglec-ganglioside interactions are described; these methods can be applied to further our understanding of gangliosides as Siglec ligands and the physiological and pathophysiological roles that they mediate.
Indexed as
Identifiers
42613527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.